Marcio Souza, Praxis CEO
FDA tells Praxis it can't move into the clinic just yet for a rare epilepsy drug
The FDA emailed Praxis Precision Medicines on Thursday to let the biotech know that its IND for a rare epilepsy drug was placed on clinical …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
